The Immune Interface of Age: Neonatal and Adult Host Responses to Monkeypox Virus Infection
DOI:
https://doi.org/10.63682/jns.v14i18S.5518Keywords:
Monkey pox, neonates, immune system, cytokine stormAbstract
The emerging zoonotic pathogen Monkeypox virus (MPXV) produces separate clinical outcomes between age groups because young and older individuals possess varying levels of immune system development. The review examines the host-specific events that occur in both adult and newborn immune systems when exposed to Monkeypox virus. Neonates experience suspicion to systemic spread, limited interferon responses and subpar viral clearance because they have underdeveloped immune systems. The immune system of adult hosts generates strong Th1-dominated defense mechanisms which result in better viral control. High-grade immune reactions in adults may create tissue damage in major infection manifestations. The evaluation investigates how aging affects skin protection mechanisms and the way cytokines work and antigen-presenting cells perform their responsibilities. Medical treatments with appropriate age considerations and vaccination administration strategies and public health policies need accurate understanding of age-specific immune properties. The understanding of immunological age interactions enables researchers to develop individualized interventions which will enhance outcomes for various patient groups throughout MPXV outbreaks.
Downloads
Metrics
References
Yi XM, Lei YL, Li M, et al (2024) The monkeypox virus-host interplays. Cell Insight 3:100185. https://doi.org/10.1016/J.CELLIN.2024.100185
Karagoz A, Tombuloglu H, Alsaeed M, et al (2023) Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. J Infect Public Health 16:531–541. https://doi.org/10.1016/J.JIPH.2023.02.003
Harapan H, Ophinni Y, Megawati D, et al (2022) Monkeypox: A Comprehensive Review. Viruses 14:2155. https://doi.org/10.3390/V14102155
Chen N, Li G, Liszewski MK, et al (2005) Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340:46–63. https://doi.org/10.1016/J.VIROL.2005.05.030
Haller SL, Peng C, McFadden G, Rothenburg S (2014) Poxviruses and the evolution of host range and virulence. Infect Genet Evol 21:15–40. https://doi.org/10.1016/J.MEEGID.2013.10.014
Shchelkunov SN, Totmenin A V., Safronov PF, et al (2002) Analysis of the Monkeypox Virus Genome. Virology 297:172–194. https://doi.org/10.1006/VIRO.2002.1446
Kaler J, Hussain A, Flores G, et al (2022) Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. Cureus 14:1–11. https://doi.org/10.7759/cureus.26531
McCollum AM, Damon IK (2014) Human monkeypox. Clin Infect Dis 58:260–267. https://doi.org/10.1093/cid/cit703
Rampogu S, Kim Y, Kim SW, Lee KW (2023) An overview on monkeypox virus: Pathogenesis, transmission, host interaction and therapeutics. Front Cell Infect Microbiol 13:1–12. https://doi.org/10.3389/fcimb.2023.1076251
Sklenovská N, Van Ranst M (2018) Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans. Front public Heal 6:. https://doi.org/10.3389/FPUBH.2018.00241
Fleischauer AT, Kile JC, Davidson M, et al (2005) Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis 40:689–694. https://doi.org/10.1086/427805
Vaughan A, Aarons E, Astbury J, et al (2020) Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018. Emerg Infect Dis 26:782. https://doi.org/10.3201/EID2604.191164
Sah R, Abdelaal A, Reda A, et al (2022) Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence? Pathog 2022, Vol 11, Page 924 11:924. https://doi.org/10.3390/PATHOGENS11080924
Dye C, Kraemer MUG (2022) Investigating the monkeypox outbreak. BMJ 377:. https://doi.org/10.1136/BMJ.O1314
Reed KD, Melski JW, Graham MB, et al (2004) The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350:342–350. https://doi.org/10.1056/NEJMOA032299
Vivancos R, Anderson C, Blomquist P, et al (2022) Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill 27:. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200422
Bragazzi NL, Kong JD, Mahroum N, et al (2023) Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review. J Med Virol 95:. https://doi.org/10.1002/JMV.27931
Dashraath P, Nielsen-Saines K, Rimoin A, et al (2022) Monkeypox in pregnancy: virology, clinical presentation, and obstetric management. Am J Obstet Gynecol 227:849-861.e7. https://doi.org/10.1016/J.AJOG.2022.08.017
Mbala PK, Huggins JW, Riu-Rovira T, et al (2017) Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo. J Infect Dis 216:824–828. https://doi.org/10.1093/INFDIS/JIX260
Huang AKARSC (2022) Human Monkeypox without Viral Prodrome or Sexual Exposure, California, USA, 2022. Emerg Infect Dis 28:2121–2123
Zaucha GM, Jahrling PB, Geisbert TW, et al (2001) The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Investig 81:1581–1600. https://doi.org/10.1038/LABINVEST.3780373
Hutson CL, Olson VA, Carroll DD, et al (2009) A prairie dog animal model of systemic orthopoxvirus disease using west African and Congo Basin strains of Monkeypox virus. J Gen Virol 90:323–333. https://doi.org/10.1099/VIR.0.005108-0
Lu J, Xing H, Wang C, et al (2023) Mpox (formerly monkeypox): pathogenesis, prevention, and treatment. Signal Transduct. Target. Ther. 8
Islam MA, Mumin J, Haque MM, et al (2023) Monkeypox virus (MPXV): A Brief account of global spread, epidemiology, virology, clinical features, pathogenesis, and therapeutic interventions. Infect Med 2:262–272. https://doi.org/10.1016/J.IMJ.2023.11.001
Basha S, Surendran N, Pichichero M (2014) Immune Responses in Neonates. Expert Rev Clin Immunol 10:1171. https://doi.org/10.1586/1744666X.2014.942288
Simon AK, Hollander GA, McMichael A (2015) Evolution of the immune system in humans from infancy to old age. Proc R Soc B Biol Sci 282:20143085. https://doi.org/10.1098/RSPB.2014.3085
Feng E, Balint E, Poznanski SM, et al (2021) Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes. Cells 10:708. https://doi.org/10.3390/CELLS10030708
Agrati C, Cossarizza A, Mazzotta V, et al (2022) Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study. Lancet Infect Dis 23:320. https://doi.org/10.1016/S1473-3099(22)00662-4
Hetta HF, Alharbi AA, Alsharif SM, et al (2024) Mpox Virus Infection and Vaccination: Immunopathogenesis and Exploring the Link to Neuropsychiatric Manifestations. Immuno 2024, Vol 4, Pages 578-600 4:578–600. https://doi.org/10.3390/IMMUNO4040034
Jiang RM, Zheng YJ, Zhou L, et al (2022) Diagnosis, treatment, and prevention of monkeypox in children: an experts’ consensus statement. World J Pediatr 19:231. https://doi.org/10.1007/S12519-022-00624-3
Reuter S, Moser C, Baack M (2014) Respiratory Distress in the Newborn. Pediatr Rev 35:417. https://doi.org/10.1542/PIR.35-10-417
Hussain A, Kaler J, Lau G, Maxwell T (2022) Clinical Conundrums: Differentiating Monkeypox From Similarly Presenting Infections. Cureus 14:e29929. https://doi.org/10.7759/CUREUS.29929
Maredia H, Sartori-Valinotti JC, Ranganath N, et al (2023) Supportive Care Management Recommendations for Mucocutaneous Manifestations of Monkeypox Infection. Mayo Clin Proc 98:828. https://doi.org/10.1016/J.MAYOCP.2023.01.019
Ramel SE, Brown LD, Georgieff MK (2014) The Impact of Neonatal Illness on Nutritional Requirements—One Size Does Not Fit All. Curr Pediatr Rep 2:248. https://doi.org/10.1007/S40124-014-0059-3
van Nispen C, Reffett T, Long B, et al (2022) Diagnosis and Management of Monkeypox: A Review for the Emergency Clinician. Ann Emerg Med 81:20. https://doi.org/10.1016/J.ANNEMERGMED.2022.07.014
Niaz F, Tariq S, Ali SM, et al (2022) Monkeypox treatment: Is tecovirimat the answer? J Infect Public Health 15:1297. https://doi.org/10.1016/J.JIPH.2022.10.012
Russo AT, Grosenbach DW, Chinsangaram J, et al (2020) An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 19:331. https://doi.org/10.1080/14787210.2020.1819791
Ganapthy D, Sekaran S, Rajamani Sekar SK (2023) Monkeypox treatment options: current status of antiviral drugs - a correspondence. Int J Surg 109:. https://doi.org/10.1097/JS9.0000000000000147
DeLaurentis CE, Kiser J, Zucker J (2022) New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. Antimicrob. Agents Chemother. 66
Yu PA, Elmor R, Muhammad K, et al (2024) Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023. NEJM Evid 3:EVIDoa2400189. https://doi.org/10.1056/EVIDOA2400189
McMullan LK, Flint M, Dyall J, et al (2016) The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res 125:. https://doi.org/10.1016/j.antiviral.2015.10.010
Magee WC, Hostetler KY, Evans DH (2005) Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49:. https://doi.org/10.1128/AAC.49.8.3153-3162.2005
Cinatl J, Bechtel M, Reus P, et al (2024) Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models. J Med Virol 96:. https://doi.org/10.1002/JMV.29354
Siegrist EA, Sassine J (2022) Antivirals With Activity Against Mpox: A Clinically Oriented Review. Clin Infect Dis An Off Publ Infect Dis Soc Am 76:155. https://doi.org/10.1093/CID/CIAC622
Grosenbach DW, Jordan R, Hruby DE (2011) Development of the small-molecule antiviral ST-246® as a smallpox therapeutic. Future Virol 6:653–671. https://doi.org/10.2217/FVL.11.27
Grabenstein JD, Hacker A (2024) Vaccines against mpox: MVA-BN and LC16m8. Expert Rev Vaccines 23:796–811. https://doi.org/10.1080/14760584.2024.2397006
Garcia-Atutxa I, Mondragon-Teran P, Huerta-Saquero A, Villanueva-Flores F (2024) Advancements in monkeypox vaccines development: a critical review of emerging technologies. Front Immunol 15:1456060. https://doi.org/10.3389/FIMMU.2024.1456060
Sagdat K, Batyrkhan A, Kanayeva D (2024) Exploring monkeypox virus proteins and rapid detection techniques. Front Cell Infect Microbiol 14:1414224. https://doi.org/10.3389/FCIMB.2024.1414224/TEXT
Tang D, Liu X, Lu J, et al (2023) Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge. Front Immunol 14:. https://doi.org/10.3389/FIMMU.2023.1203410
Paparini S, Whelan I, Mwendera C, et al (2024) Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches. Infect Dis (London, England) 56:589. https://doi.org/10.1080/23744235.2024.2364801
Dubey T, Chakole S, Agrawal S, et al (2023) Enhancing Nursing Care in Monkeypox (Mpox) Patients: Differential Diagnoses, Prevention Measures, and Therapeutic Interventions. Cureus 15:e44687. https://doi.org/10.7759/CUREUS.44687
Rabaan AA, Al-Shwaikh SA, Alfouzan WA, et al (2023) A Comprehensive Review on Monkeypox Viral Disease with Potential Diagnostics and Therapeutic Options. Biomedicines 11:1826. https://doi.org/10.3390/BIOMEDICINES11071826
Laupèze B, Del Giudice G, Doherty MT, Van der Most R (2021) Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines 6:93. https://doi.org/10.1038/S41541-021-00354-Z
Amer F, Khalifa HES, Elahmady M, et al (2023) Mpox: Risks and approaches to prevention. J Infect Public Health 16:901. https://doi.org/10.1016/J.JIPH.2023.04.001
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
